Revisiting Ibd Management: Dogmas to Be Challenged

Table of Contents

• Preliminary Pages
• Title Page
• Table of Contents

• Introduction
• Challenging Dogmas in IBD
  D’Haens, G.

• IBD Is a Disorder of Defective Autophagy and Innate Immunity
• Evidence from Genetics for a Role of Autophagy and Innate Immunity in IBD Pathogenesis
  Parkes, M.
• Commensal-Innate Immune Miscommunication in IBD Pathogenesis
  Cario, E.
• Endoplasmic Reticulum Stress and Inflammation
  Adolph, T.-E. ; Niederreiter, L. ; Blumberg, R.S. ; Kaser, A.

• No Bacteria, No IBD
• Lessons from Diversion Studies and Antibacterial Interventions
  Flanagan, P.K. ; Campbell, B.J. ; Rhodes, J.M.
• Bacteriology in the Etiopathogenesis of Pouchitis
  Shen, B.
• The Role of Anti(myco)bacterial Interventions in the Management of IBD: Is There Evidence at All?
  Pineton de Chambrun, G.P. ; Torres, J. ; Darfeuille-Michaud, A. ; Colombel, J.-F.

• Steroids Are Useful for the Management of IBD
• Second-Generation Corticosteroids for the Treatment of Crohn’s Disease and Ulcerative Colitis: More Effective and Less Side Effects?
  De Cassan, C. ; Fiorino, G. ; Danese, S.

• Early and Late Crohn’s Disease Are Distinct Entities
• Epidemiology of the Transition from Early to Late Crohn’s Disease
  Louis, E.
• Markers That Differentiate Early from Late IBD
  Huang, C. ; Kugathasan, S.

• Innovative Treatments Will Offer a Better Outcome for Patients with IBD
• Biologic Therapies: Lessons from Multiple Sclerosis
  Ghosh, S.
• Current Status of Mesenchymal Stem Cell Therapy and Bone Marrow Transplantation in IBD
  Ricart, E.
• Reprogramming the Immune System in IBD
  MacDonald, T.T. ; Vossenkaemper, A. ; Fantini, M. ; Monteleone, G.

• Patient-Tailored Therapies Are Superior to Algorithmic Approaches in IBD
• How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD?
  Rutgeerts, P.
• Treat the Patient or Treat the Disease?
  Hanauer, S.B. ; Kirsner, J.B.

• Immunosuppression Puts IBD Patients at Risk for Severe Complications
• Combined Immunosuppression Is More Dangerous than Monotherapy: What Is Fact and What Is Fiction?
  Schölmerich, J.
• Prevention and Management of Infectious Complications in IBD
  Rahier, J.-F.
• Immunosuppression-Related Lymphomas and Cancers in IBD: How Can They Be Prevented?
  Beaugerie, L.
• How to Manage IBD in Patients with Infections or Malignancies?
  Kohn, A. ; Meddi, P.

• Leaving the Dogmas Behind and Looking into the Future
• Towards a Novel Molecular Classification of IBD
  Vermeire, S.
• Towards a ‘Cure’ for IBD
  Fiocchi, C.

• Further Section
• Falk Symposium Series
• Author Index
• Subject Index